Ask a table of people in St. Charles what they think about ketamine therapy for depression and you will not get a fight. You will get a few shrugs, one raised eyebrow, and several people who have never heard of the thing you are describing.
We paid to ask properly. Our survey gave 443 adults across ten Midwest states a plain description of ketamine-family treatment for low mood and trauma, then asked for an unedited first reaction. The answers fell into five uneven piles. Smallest first: negative at 9 percent, then two piles of 18 percent each (never heard of it; hopeful or curious), skeptical at 21, and cautious but open, the biggest, at 34.
Stack the two friendly piles and 51 percent lean toward yes; the flat no is 9 percent. These numbers are final, and the shape of the room is clear.
Comparing the piles, not the headlines
One headline could truthfully say half of Midwest adults are open to ketamine therapy. Another could truthfully say only about one in five respondents is enthusiastic. Both come from the same five numbers, which is why the columns are worth reading side by side.
The largest group is cautious but open, and that is not a soft yes. Caution is a demand for evidence, and it is the most common posture in the sample by a wide margin. Skeptics came second at 21 percent; add the 9 percent who answered negatively and the doubting side of the room reaches 31 percent.
So the real comparison is 51 percent leaning yes against 31 percent leaning no, with 18 percent standing outside the conversation because nobody has mentioned this to them.
The unaware column is the strange one
Eighteen percent of respondents said the idea of ketamine therapy for mental health was new to them. A separate question found something larger and stranger. Spravato, which is esketamine in spray form and FDA approved for depression other drugs have not eased, was unfamiliar to 73 percent of the sample. Another 21 percent knew the name as a sound and nothing more, and only 6 percent could describe it.
Put those numbers together and you find the gap behind most of the confusion here. People have a reaction to the idea of ketamine. Almost nobody has information about the approved version, so the reaction forms around the word, not the treatment.
What the whole sample says it wants
We asked everyone, not just the open half, what would actually govern the decision, and three answers dominated. Insurance coverage was among the two leading provider factors for 85 percent. For 59 percent, FDA approval would clinch the decision or come close. And their own doctor's word would get 74 percent to try it, compared with 2 percent for an ad.
Those figures describe all 443 respondents together. How the skeptical 21 percent answered them is beyond what we can report, because the survey has no breakdown by first reaction, and we will not slice a number the data does not contain. The sample as a whole asked for a regulator, a payer, and a physician before it would move.
A fair comparison of the two honest readings
Read it optimistically and hostility is rare: 9 percent hard-negative is a small wall, and most people are waiting for a reason rather than defending a position.
Read it pessimistically and nothing is won yet. A cautious but open answer costs a respondent nothing. It is a maybe, given to a stranger, about a treatment most of them could not name. Between that maybe and a real appointment sit insurance checks, a referral, and a talk with a doctor who may know little about the subject.
Fifty-one percent open is permission to explain something. It is not evidence that anyone is ready to start.
What this looks like in St. Charles County
Local context changes the practical half of the question more than the attitude half. If you live in St. Charles and a clinician agrees this is worth exploring, two questions get real fast: does your plan cover it, and how far would you drive?
Nearness to home ranked second to coverage, named in the top pair by 43 percent of respondents. That preference has teeth here, because esketamine is given at a certified site with monitoring afterward, and someone else must drive you home. If the nearest certified site is across the river, the visit is an afternoon plus a driver, not an hour. Brain Recovery Centers explains how its Spravato appointments are structured, which can help you plan the logistics before you commit.
Ask the coverage question before anything else, and ask the clinic to verify your specific plan in writing rather than describe what plans usually do. Half of our respondents would pick insured care with more hoops over paying for a faster start; 23 percent chose to pay, and the final 26 percent were unsure. That is a market willing to do paperwork, and the paperwork is worth doing.
One distinction to keep straight
Esketamine, sold as Spravato, is the approved option for depression that keeps resisting treatment, and every dose is supervised inside a certified office. IV ketamine in a clinic, and compounded ketamine mailed to your house after a video visit, are different arrangements with different oversight; the at-home one is the grayest. When a clinic says "ketamine therapy," ask which it means. Nothing in this survey shows that any of them is right for you; that call belongs to a clinician who has your records.
This article is not medical advice, and it promises no treatment will work. The numbers describe how people feel about an idea, which is different from whether the idea helps.
If depression has ever taken you to thoughts of ending your life, tell someone before you read anything else today. Call or text 988 at any hour and a Lifeline counselor will pick up; making that call takes more courage than staying quiet.
Methodology
This publisher commissioned and paid for the study, Pollfish study 395586438, run on the vendor's consumer panel; the final responses arrived June 23, 2026. A total of 443 completed responses came from a general-population sample, people 18 to 64 in Missouri, Kansas, Nebraska, Wisconsin, and six other Midwest states, rather than a screened patient panel. Shares on multi-select questions can sum above 100. Only top-line percentages are reported here. The panel provider has finished validation, and these are its final figures.